Reclassifying high-risk primary prevention: real-world LDL-C reduction with bempedoic acid in a multimorbid rural population

23 April 2026 (08:00 - 18:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Carl Deaney

Louth (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Urate dynamics, gout events, and tolerability of bempedoic acid for primary ASCVD prevention: a real-world retrospective review from rural primary care in England

Mrs M. Donaldson (Louth, GB)

Abstract Slides

Presentation thumbnail

Impact of revised 2025 ESC/EAS guidelines for the management of dyslipidaemias in the community

Doctor N. Ahanchi (Fribourg, CH)

Abstract Slides

Presentation thumbnail

Nurse-led secondary prevention lipid clinic

Mr A. Young (Bournemouth, GB)

Abstract Slides

Presentation thumbnail

Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis

Associate Professor E. Begic (Sarajevo, BA)

Abstract Slides

Presentation thumbnail

Low density lipoprotein-Cholesterol levels evaluation in the total population and subgroup of non-diabetic dyslipidemic Greek patients of ZEUS study under fixed-dose-combination ezetimibe/rosuvastatin

Mr G. Tsioumas (Athens, GR)

Abstract Slides

Access the full session

Session thumbnail

Achieving lipid goals in the real world (1)

The Event

Event poster

ESC Preventive Cardiology 2026

23 April - 25 April 2026

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources